Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-6.42 Insider Own1.81% Shs Outstand7.95M Perf Week1.22%
Market Cap4.10M Forward P/E- EPS next Y-1.41 Insider Trans0.00% Shs Float7.81M Perf Month-30.24%
Income-15.11M PEG- EPS next Q-0.55 Inst Own6.14% Short Float1.95% Perf Quarter-43.29%
Sales0.00M P/S- EPS this Y74.35% Inst Trans-6.53% Short Ratio0.31 Perf Half Y-59.98%
Book/sh0.89 P/B0.58 EPS next Y32.21% ROA-122.08% Short Interest0.15M Perf Year-82.14%
Cash/sh0.80 P/C0.65 EPS next 5Y- ROE-178.57% 52W Range0.41 - 3.90 Perf YTD-60.29%
Dividend Est.- P/FCF- EPS past 5Y71.22% ROI-233.19% 52W High-86.76% Beta0.73
Dividend TTM- Quick Ratio3.48 Sales past 5Y-20.00% Gross Margin- 52W Low25.90% ATR (14)0.06
Dividend Ex-DateApr 23, 2008 Current Ratio3.48 EPS Y/Y TTM39.74% Oper. Margin0.00% RSI (14)33.82 Volatility12.79% 10.21%
Employees7 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q73.42% Payout- Rel Volume0.31 Prev Close0.51
Sales Surprise- EPS Surprise21.29% Sales Q/Q- EarningsMay 15 BMO Avg Volume490.86K Price0.52
SMA20-15.12% SMA50-30.74% SMA200-57.16% Trades Volume150,097 Change1.89%
Jul-10-24 08:00AM
Jun-28-24 08:00AM
Jun-25-24 08:00AM
May-30-24 08:00AM
May-20-24 11:54AM
07:45AM Loading…
May-15-24 06:00AM
May-14-24 08:00AM
May-08-24 07:00AM
May-02-24 05:50PM
Apr-12-24 12:00PM
Apr-01-24 10:53AM
Mar-26-24 07:00AM
Mar-19-24 07:00AM
Mar-12-24 07:00AM
02:04PM Loading…
Feb-29-24 02:04PM
Feb-26-24 08:00AM
Feb-23-24 08:00AM
Feb-21-24 08:00AM
Jan-03-24 08:00AM
Dec-29-23 08:52AM
Dec-28-23 08:00AM
Dec-27-23 08:00AM
Dec-20-23 08:00AM
Dec-05-23 08:00AM
Nov-29-23 08:00AM
Nov-27-23 08:00AM
Nov-24-23 08:00AM
Nov-13-23 04:01PM
08:00AM Loading…
Oct-31-23 08:00AM
Oct-20-23 08:00AM
Oct-18-23 08:00AM
Oct-11-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-20-23 08:00AM
Sep-18-23 08:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-30-23 08:00AM
Aug-28-23 11:04AM
Aug-24-23 08:00AM
Aug-21-23 08:00AM
Aug-14-23 08:00AM
Jul-24-23 08:00AM
Jul-17-23 08:00AM
Jun-26-23 08:00AM
Jun-12-23 08:00AM
Jun-07-23 08:00AM
Jun-05-23 08:00AM
May-30-23 08:00AM
May-24-23 08:00AM
May-22-23 08:00AM
May-19-23 08:00AM
May-18-23 08:00AM
May-15-23 09:25AM
May-02-23 07:30AM
Apr-10-23 07:30AM
Apr-03-23 04:05PM
Mar-23-23 07:30AM
Mar-21-23 07:33AM
Mar-14-23 07:30AM
Feb-28-23 07:30AM
Feb-23-23 07:33AM
Feb-22-23 07:33AM
Feb-01-23 07:33AM
Dec-21-22 07:30AM
Nov-28-22 07:30AM
Nov-16-22 07:30AM
Nov-01-22 07:30AM
Oct-24-22 07:00AM
Oct-12-22 08:00AM
Aug-31-22 07:30AM
Jul-27-22 07:30AM
Jul-26-22 05:30PM
Jul-25-22 08:00AM
Jul-19-22 07:30AM
Jul-14-22 12:15PM
Jul-13-22 07:30AM
Jun-08-22 07:30AM
May-24-22 04:05PM
May-17-22 07:30AM
May-11-22 07:30AM
May-05-22 07:30AM
May-03-22 05:13PM
Apr-29-22 08:35AM
Apr-25-22 08:35AM
Apr-06-22 07:30AM
Mar-31-22 05:02PM
Mar-29-22 07:30AM
Mar-15-22 07:30AM
Mar-03-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Feb-15-22 04:05PM
Feb-11-22 08:30AM
Feb-08-22 04:45PM
Jan-18-22 07:30AM
Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company was founded on February 28, 1994 and is headquartered in Naples, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PASQUALONE FRANKDirectorSep 15 '23Buy2.141,0002,1401,000Sep 19 05:34 PM